TKM-Ebola

TKM-Ebola is an experimental drug for the treatment of the Ebola virus disease. It is developed by Tekmira Pharmaceuticals, a Canadian pharmaceutical company. The drug is a small interfering RNA (siRNA) treatment designed to inhibit the replication of the Ebola virus.

History

TKM-Ebola was first developed in the early 2010s. In 2014, the drug was fast-tracked by the Food and Drug Administration (FDA) for use in humans following a successful trial in primates. However, the FDA placed a clinical hold on the drug in July 2014 due to safety concerns. The hold was partially lifted in August 2014, allowing the drug to be used in emergency cases.

Mechanism of Action

TKM-Ebola works by using siRNA to inhibit the replication of the Ebola virus. The siRNA is encapsulated in lipid nanoparticles to protect it from degradation and to enhance its delivery to target cells. Once inside the cell, the siRNA binds to the Ebola virus RNA and triggers its degradation, preventing the virus from replicating.

Clinical Trials

Several clinical trials have been conducted to test the safety and efficacy of TKM-Ebola. In a Phase I trial, the drug was found to be safe and well-tolerated. However, a Phase II trial was put on hold due to safety concerns. The drug has also been used on a compassionate use basis in patients with Ebola virus disease.

See Also

• Ebola virus disease
• Tekmira Pharmaceuticals
• Food and Drug Administration

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia